Apollomics, Inc. (NASDAQ:APLMW) Short Interest Down 61.9% in January

Apollomics, Inc. (NASDAQ:APLMW) was the target of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 7,200 shares, a decline of 61.9% from the January 15th total of 18,900 shares. Based on an average daily volume of 86,900 shares, the short-interest ratio is currently 0.1 days.

Apollomics Price Performance

NASDAQ:APLMW opened at $0.01 on Thursday. The stock has a 50-day simple moving average of $0.01 and a two-hundred day simple moving average of $0.01. Apollomics has a 52-week low of $0.01 and a 52-week high of $0.04.

Apollomics Company Profile

Apollomics, Inc, a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.